Dendritic cell immunotherapy in uterine cancer.

Abstract

Uterine cancer is the most common pelvic gynecological malignancy. Uterine sarcomas and relapsed uterine carcinomas have limited treatment options. The search for new therapies is urgent. Dendritic cell (DC) immunotherapy holds much promise, though has been poorly explored in uterine cancer. This commentary gives an insight in existing DC immunotherapy studies in uterine cancer and summarizes the possibilities and the importance of the loading of tumor antigens onto DC and their subsequent maturation. However, the sole application of DC immunotherapy to target uterine cancer will be insufficient because of tumor-induced immunosuppression, which will hamper the establishment of an effective anti-tumor immune response. The authors give an overview on the limited existing immunosuppressive data and propose a novel approach on DC immunotherapy in uterine cancer.

• Authors: An Coosemans, Sandra Tuyaerts, Anke Vanderstraeten, Ignace Vergote, Frédéric Amant, Stefaan W Van Gool
• Journal: Human vaccines & immunotherapeutics (Hum Vaccin Immunother) Vol. 10 Issue 7 Pg. 1822-7 ( 2014) ISSN: 2164-554X [Electronic] United States
• PMID: 25424788 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Topics

• Carcinoma (therapy)
• Dendritic Cells (immunology)
• Female
• Humans
• Immune Tolerance
• Immunotherapy (methods)
• Sarcoma (therapy)
• Uterine Neoplasms (immunology, therapy)